Last reviewed · How we verify

ADJUNTIVE ANTIBIOTICS

University of Valencia · FDA-approved active Small molecule

ADJUNTIVE ANTIBIOTICS is a Antibiotic combination therapy Small molecule drug developed by University of Valencia. It is currently FDA-approved for Serious bacterial infections requiring combination antimicrobial therapy, Polymicrobial infections.

Adjunctive antibiotics are antimicrobial agents used in combination with other treatments to enhance therapeutic efficacy and reduce microbial resistance.

Adjunctive antibiotics are antimicrobial agents used in combination with other treatments to enhance therapeutic efficacy by targeting bacterial infections or modulating the microbiome. Used for Adjunctive treatment in bacterial infections (specific indications not clearly defined in available information).

At a glance

Generic nameADJUNTIVE ANTIBIOTICS
SponsorUniversity of Valencia
Drug classAntibiotic combination therapy
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhaseFDA-approved

Mechanism of action

Adjunctive antibiotics work by combining multiple antimicrobial agents with complementary mechanisms of action to broaden spectrum coverage, improve bacterial killing, and reduce the likelihood of resistance development. This combination approach is commonly used in serious infections where monotherapy may be insufficient or where synergistic effects between agents provide clinical benefit.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about ADJUNTIVE ANTIBIOTICS

What is ADJUNTIVE ANTIBIOTICS?

ADJUNTIVE ANTIBIOTICS is a Antibiotic combination therapy drug developed by University of Valencia, indicated for Serious bacterial infections requiring combination antimicrobial therapy, Polymicrobial infections.

How does ADJUNTIVE ANTIBIOTICS work?

Adjunctive antibiotics are antimicrobial agents used in combination with other treatments to enhance therapeutic efficacy and reduce microbial resistance.

What is ADJUNTIVE ANTIBIOTICS used for?

ADJUNTIVE ANTIBIOTICS is indicated for Serious bacterial infections requiring combination antimicrobial therapy, Polymicrobial infections.

Who makes ADJUNTIVE ANTIBIOTICS?

ADJUNTIVE ANTIBIOTICS is developed and marketed by University of Valencia (see full University of Valencia pipeline at /company/university-of-valencia).

What drug class is ADJUNTIVE ANTIBIOTICS in?

ADJUNTIVE ANTIBIOTICS belongs to the Antibiotic combination therapy class. See all Antibiotic combination therapy drugs at /class/antibiotic-combination-therapy.

What development phase is ADJUNTIVE ANTIBIOTICS in?

ADJUNTIVE ANTIBIOTICS is FDA-approved (marketed).

What are the side effects of ADJUNTIVE ANTIBIOTICS?

Common side effects of ADJUNTIVE ANTIBIOTICS include Gastrointestinal disturbances, Allergic reactions, Drug interactions, Nephrotoxicity.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing